A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured anti-BCMA CAR T cells (BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (r/r MM) (Papilio-1)

Study title: 
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured anti-BCMA CAR T cells (BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (r/r MM) (Papilio-1)
Long title: 
A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured anti-BCMA CAR T cells (BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (r/r MM) (Papilio-1)
Date receipt dossier: 
7 Jun 2022
EudraCT number: 
2022-500782-27
Pharmaceutical study code: 
BCMACP03
Company / Sponsor: 
CellPoint B.V.
Phase: 
I/II
Treated organism: 
Humans
Indication category: 
Cancer therapy
Disease: 
Multiple Myeloma
Therapeutic approach: 
Immunotherapy
Genetic modification: 
BCMA CAR
Method of transfer of nucleic acid of interest: 
Lentiviral vector
Administered biological material: 
Autologous T cells transduced with lentiviral vectors expressing BCMA-CAR
Route of administration: 
Intravenous
Locations in Belgium: 
CHU de Liège, UZA
Type of procedure: 
Contained use only
Current status: 
Authorized